Penumbra, Inc.

156 articles with Penumbra, Inc.

• Penumbra, Inc. to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

  8/31/2021

  Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021.

• Penumbra, Inc. to Present at the 2021 Wells Fargo Virtual Healthcare Conference

  8/26/2021

  Penumbra, Inc. announced that its management team is scheduled to present at the 2021 Wells Fargo Virtual Healthcare Conference on Thursday, September 9, 2021.

• Penumbra Introduces REAL® i-Series™, Expanding REAL Immersive System to Support Broad Range of Care Providers and Mental Health Professionals

  8/10/2021

  Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced the introduction of the REAL® Immersive System i-Series™, offering engaging, immersive, gaze-based experiences and activities to care providers and mental health professionals.

• Penumbra, Inc. Reports Second Quarter 2021 Financial Results

  8/9/2021

  Penumbra, Inc.Penumbra, Inc., a global healthcare company focused on innovative therapies, reported financial results for the second quarter ended June 30, 2021.

• Penumbra, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference

  7/28/2021

  Penumbra, Inc. announced that its management team is scheduled to present at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021.

• Penumbra, Inc. Schedules Second Quarter 2021 Earnings Release and Conference Call for August 9, 2021

  7/12/2021

  Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2021 after market close on Monday, August 9, 2021 at 4:30 PM Eastern Time

• Penumbra Receives FDA Clearance for RED 62 Reperfusion Catheter, Enabling Physicians to Address Broad Range of Stroke Patients

  6/23/2021

  Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and commercial availability of the RED™ 62 Reperfusion Catheter, the latest addition to the company’s comprehensive Penumbra System®

• Penumbra, Inc. to Present at the William Blair 41st Annual Growth Stock Virtual Conference

  5/18/2021

  Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the William Blair 41st Annual Growth Stock Virtual Conference on Tuesday, June 1, 2021 .

• Penumbra, Inc. Reports First Quarter 2021 Financial Results

  5/4/2021

  Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2021.

• Penumbra, Inc. to Present at the BofA Securities 2021 Virtual Health Care Conference

  4/27/2021

  Penumbra, Inc. announced that its management team is scheduled to present at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021.

• Penumbra, Inc. Schedules First Quarter 2021 Earnings Release and Conference Call for May 4, 2021

  4/13/2021

  Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2021 after market close on Tuesday, May 4, 2021 at 4:30 PM Eastern Time

• Penumbra, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results

  2/23/2021

  Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2020.

• Penumbra, Inc. to Present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference

  2/10/2021

  Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on Wednesday, February 24, 2021 .

• Penumbra, Inc. Schedules Fourth Quarter and Full Year 2020 Earnings Release and Conference Call for February 23, 2021

  2/2/2021

   Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2020 after market close on Tuesday, February 23, 2021 at 4:30 PM Eastern Time . A press release with fourth quarter and full year 2020 financial results will be issued after market

• Penumbra Announces Preliminary Unaudited Revenue for the Fourth Quarter and Full Year 2020

  1/11/2021

  Penumbra, Inc. (the "Company") ( NYSE: PEN ), a global healthcare company focused on innovative therapies, today announced certain unaudited preliminary revenue results for the fourth quarter and full year 2020 ahead of its participation at the 39 th Annual J.P. Morgan Healthcare Conference on January 11-14, 2021 .

• Penumbra, Inc. to Present at the 39th Annual J.P. Morgan Healthcare Conference

  12/29/2020

  Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021.

• Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall

  12/15/2020

  Penumbra, Inc. (NYSE: PEN) today announced that it is voluntarily recalling all configurations of the Penumbra JET® 7 Reperfusion Catheter with Xtra Flex technology (JET 7 Xtra Flex)

• Penumbra Responds to False Allegations from Short Sellers Seeking to Manipulate Company Stock and Remove Life-saving Medical Devices from the Market

  12/8/2020

  Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today responded to recent attacks by short sellers containing inaccurate and misleading information regarding scientific research published by Penumbra's co-founder and Chief Innovator, Arani Bose , MD.

• Penumbra, Inc. to Participate in CEO Discussion with Bank of America

  12/4/2020

  Penumbra, Inc. (NYSE: PEN) today announced that its chief executive officer is scheduled to participate in a discussion with Bank of America on Tuesday, December 8, 2020.

• Penumbra’s Newest Generation of Indigo Aspiration System Receives FDA Clearance for Pulmonary Embolism

  11/20/2020

  Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. Food and Drug Administration 510(k) clearance for expanded indication of the latest iteration of the Indigo® Aspiration System, Lightning™ 12.